Has Sean Amsbaugh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,631 in general payments to Sean Amsbaugh, MD across 143 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sean Amsbaugh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sean Amsbaugh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sean Amsbaugh, MD

Dermatopathology · Aurora, CONPI 1073561007

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $857 and has fallen 72.5% since, to $236 in 2025.

$3,631in general payments, 2019–2025

Across 143 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$724
Sun Pharmaceutical Industries Inc.$574
Sanofi$339
Lilly USA, LLC$334
Amgen$311
Johnson & Johnson$274
plus $1K from 17 others

What the payments were for

Food & beverage$3,59999%
Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	28	$724
Sun Pharmaceutical Industries Inc.	19	$574
Sanofi	6	$339
Lilly USA, LLC	10	$334
Amgen	11	$311
Johnson & Johnson	13	$274
Dermavant Sciences, Inc.	3	$152
LEO Pharma Inc.	11	$141
Incyte Corporation	9	$135
Regeneron Healthcare Solutions, Inc.	4	$117
Pfizer	5	$84
Strata Skin Sciences, Inc.	1	$77
Ortho Dermatologics, A Division Of Bausch Health US, LLC	5	$76
Galderma Laboratories, L.p.	4	$70
E.r. Squibb & Sons, L.L.C.	2	$46
DUSA Pharmaceuticals, Inc.	2	$39
VYNE Pharmaceuticals Inc.	2	$39
Almirall LLC	3	$38
Botanix SB Inc	1	$16
Genentech USA, Inc.	1	$16
Helsinn Therapeutics (U.S.), Inc.	1	$15
UCB, Inc.	1	$12
Organon	1	$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few dermatopathology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$362,789

Medicare patients

3,052

Services billed

8,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Doxycycline Hyclate	57	$1,851
Fluorouracil	17	$1,402
Metronidazole	23	$1,372
Clobetasol Propionate	23	$910
Doxycycline Monohydrate	52	$784
Hydroxychloroquine Sulfate	21	$701
Mycophenolate Mofetil	17	$488
Triamcinolone Acetonide	39	$273
Minoxidil	14	$200
Ketoconazole	12	$191
Nystatin	19	$166

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Aurora

James HuffAurora$591
Whitney HighAurora$165
Aaron HooverGreeley$7K
Ingerlisa MattochLoveland$5K
Sarah BairLoveland$2K
Jean UrquhartEagle$744
Robert WrightDenver$229
Sidney HoskinsDurango$205
Edward WrightRifle$136
Narina GroveLoveland$48

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →